After raising 5.5 million euros in 2022, Lys Therapeutics announces that it has obtained funding of 2 million euros from Bpifrance, in support of deeptech development. This aid, consisting partly of grants and partly of repayable advances, is intended to accelerate the pharmaceutical development of Lys Therapeutics’ drug candidate, targeting neurological diseases. This new financing will allow the company, based in Caen and with a site in Lyon, to industrialize its production to the GMP standard (good manufacturing practices), necessary for the start of future clinical trials.
